% | $
Quotes you view appear here for quick access.

BioTelemetry, Inc. Message Board

baxterjames120 141 posts  |  Last Activity: Jun 20, 2016 9:32 PM Member since: Dec 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • baxterjames120 by baxterjames120 Jun 20, 2016 9:32 PM Flag

    mmune Pharmaceuticals is on a mission to improve patients’ lives through targeted medicine. The company is well-funded by a diverse investment base. Clinical work focuses on severe and/or rare inflammatory diseases and cancer.

    What Many Investors May Not Know About IMNP:

    Our lead asset, Bertilimumab, is a first in class antibody, with on going phase 2 trials in multiple indications and potential sales of $ 5B per year
    Our Immuno-Oncology pipeline, includes 3 mid-to-late stage assets and two platforms with a focus on check point inhibitors.
    NanoCyclo is a potentially game changing topical treatment for atopic dermatitis and psoriasis with potential sales of $1B and 505(b)2 accelerated track.
    IMNP NYC based new management team is poised for execution with multiple 2016-17 milestones.

    mmune Pharmaceuticals is on a mission to improve patients’ lives through targeted medicine. The company is well-funded by a diverse investment base. Clinical work focuses on severe and/or rare inflammatory diseases and cancer.

    What Many Investors May Not Know About IMNP:

    Our lead asset, Bertilimumab, is a first in class antibody, with on going phase 2 trials in multiple indications and potential sales of $ 5B per year
    Our Immuno-Oncology pipeline, includes 3 mid-to-late stage assets and two platforms with a focus on check point inhibitors.
    NanoCyclo is a potentially game changing topical treatment for atopic dermatitis and psoriasis with potential sales of $1B and 505(b)2 accelerated track.
    IMNP NYC based new management team is poised for execution with multiple 2016-17 milestones.

  • .52+ for close.

  • Why is he still "proposed" Are their legal reasons? I don't get it.

  • baxterjames120 baxterjames120 Jun 10, 2016 9:24 PM Flag

    I'm loading up more Monday. I believe we have seen the bottom. This is a long term buy and hold for those patient enough to see the incredible potential

  • Butamax and Gevo Enter Into Global Patent Cross-License and Settlement Agreements to Accelerate Development of Markets for Bio-Based Isobutanol and End All Litigation

    ENGLEWOOD, Colo., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO) and Butamax Advanced Biofuels, LLC, a joint venture between BP and DuPont, announced that they have entered into worldwide patent cross-license and settlement agreements, ending a patent dispute related to technologies for the production of bio-based isobutanol. This settlement ends all of the lawsuits and creates a new relationship between the companies, aimed at leveraging each other's strengths and accelerating development of competitive supply for bio-based isobutanol.

    The cross-license agreement grants both parties patent licenses to all fields for isobutanol and is structured to develop robust and sustainable isobutanol markets. The license will be royalty bearing for Butamax in certain fields and royalty bearing for Gevo in other fields. There are also a number of fields that are royalty-free for both companies. Both parties can sell up to 30 million gallons per year royalty-free into any field.

    The accompanying Factsheet provides further details of the cross-license and settlement agreements.

    Butamax will take the lead role in developing the market for isobutanol as an on-road gasoline blendstock. This will include progressing ongoing programs to gain required EPA approvals for mainstream use of 16% isobutanol as a gasoline blend component. Butamax has also conducted joint research with Underwriters Laboratories (UL), which has demonstrated that these blends can be used safely in fuel storage and dispensing equipment meeting current UL standards. It is expected that UL's guidance will clear the way for state government agencies to consider and approve the dispensing of biobutanol-gasoline fuel blends in the U.S.

    In parallel, Gevo will lead development of the jet fuel market. Gevo has been producing and selling alcohol-to-jet fuel (ATJ) derived from isobutanol since 2011. To date, Gevo's ATJ has been produced at its demo biorefinery in Silsbee, TX, using isobutanol produced at its Luverne, MN, fermentation facility. The company has successfully flown tests flights with the U.S. Air Force, U.S. Army, and U.S. Navy and now expects to secure the MIL-SPEC certification (JP-8 and JP-5) enabling bids on future RFPs for renewable jet fuel by the Defense Logistics Agency. Gevo also intends to begin test flights with the commercial aviation industry, including Alaska Airlines, following receipt of ASTM International certification, expected before the end of 2015.

    While Butamax and Gevo have cross-licensed all of their patents for making and using isobutanol, both parties will have their own biocatalyst and process technologies. Both Butamax and Gevo are free to license their respective technology packages to third parties. A third party licensee would be granted a sub-license, and would be subject to terms and conditions that are consistent with the cross-license between Butamax and Gevo.

    "We are very pleased to have reached this amicable and fair settlement. Setting up the marketing relationships, as we have done, brings to bear the capabilities of each of the companies," said Dr. Patrick Gruber, Gevo's Chief Executive Officer. "We very much look forward to developing a very large, growing and profitable isobutanol market in conjunction with Butamax."

    "The aim of these agreements is to accelerate development of markets for bio-based isobutanol," commented Butamax Chief Executive Officer Paul Beckwith. "This will create exciting opportunities for ethanol producers to expand their businesses by becoming isobutanol producers, at the same time enabling the most competitive isobutanol supply for customers."

    Both parties have agreed to keep all details relating to these agreements confidential, other than what is disclosed in this press release and the attachment, or is otherwise required to be disclosed by law.

    About Butamax

    Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel and chemical. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to end use. For more information, visit

    Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

    About Gevo

    Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo's strategy is to commercialize biobased alternatives to petroleum-based products to allow for the optimization of fermentation facilities' assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, Minn. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, Texas, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo has a marquee list of partners including The Coca-Cola Company, Toray Industries Inc. and Total SA, among others. Gevo is committed to a sustainable bio-based economy that meets society's needs for plentiful food and clean air and water.

  • you gotta spend money to make money. Raising cash is a good sign that production will be ramping up soon.

    Customer pipeline: Growing list of supply and development agreements in place with Sasol, Mansfield Oil, U.S. Air Force, U.S. Army, U.S. Navy, Lanxess, The Coca-Cola Company, Toray, United Airlines and others
    • Deployment status: Commissioned startup of Luverne, Minn. plant and made initial quantities of isobutanol. Currently optimizing technology to ensure isobutanol can be made in consistent and economic volumes
    • Expansion timeline: Second retrofit site identified. Construction set to commence once operational knowledge gained from Luverne is codified into optimal design

  • Time to ramp production and get new contracts. That takes money. I have no problem with the secondary. Great entry level for tomorrow.

  • tomorrow is turnaround friday.

  • no way this stays below a dollar for long! 100 million shares bought yesterday for well over a dollar.Looking for a short cover panic tomorrow.

  • never thought we would fill that gap yesterday. It's done. now lets take it higher where it belongs

  • ran down to .82 now at .87. Today should be a wild ride. Shorts have to cover at some point and there is limited downside risk from here.

  • Gevo, Inc. (NASDAQ:GEVO) shares traded 50.45% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $3.00 within the next 52-weeks. The mean target projections are based on 2 opinions, the mean target was last revised on 05/13/16. Since analyst price targets calculations are subjective, there often can be a wide range of targets from various analysts.

    Taking a broader look brokerage firms’ analysts on the street with an expectant view have high price target of $5.00 and with a conservative view have low price target of $1.00 with a standard deviation of $2.83. Standard deviation is a measure of the dispersion of a set of data from its mean. If seeing target price from optimistic overview then it has a 729 percent upside potential from the latest closing price of $0.603. This is the consensus price target based on the analysts polled by Thomson Reuters’ First Call, the average is taken from the individual analysts which provided targets and are short term projections for the 12 months.

    In terms of Buy, Sell or Hold recommendations, Gevo, Inc. (NASDAQ:GEVO) has an analyst’s mean recommendation of 2.50. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

    In order to reach at price target analysts use several metrics to determine where stock might be headed, among commonly used metrics is PEG. The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. While a high P/E ratio may make a stock look like a good buy, factoring in the company’s growth rate to get the stock’s PEG ratio can tell a different story. The lower the PEG ratio, the more the stock may be undervalued given its earnings performance. The stock has a current PEG of -0.02 where as its P/E ratio is -0.56. S&P 500 has rallied 0.33% during the last 52- weeks.

    While considering growth estimates of the company, it has next quarter growth estimates of 33.30% whereas during current quarter it has 75.50% estimations over growth, comparing to the estimations of 55.00% during current year and 31.50% for next year. Past 5 years growth of Gevo, Inc. (NASDAQ:GEVO) observed at 0.00%, looking forward for the next 5 years it has a strong prediction of 25.00% over growth.

    Gevo, Inc. (NASDAQ:GEVO)’s revenue estimates for the current quarter are $9.80 million according to 2 number of analysts, for the current quarter the company has high revenue estimates of $10.20 million in contradiction of low revenue estimates of $9.40 million. For the current year the company’s revenue estimates are $37.50 million compared to low analyst estimates of $36.80 billion and high estimates of $38.20 billion according 2 number of analysts.

    Gevo, Inc. (NASDAQ:GEVO) on June 7, 2016 announced that the first two commercial flights using Gevo’s renewable alcohol to jet fuel (ATJ) took place on June 7, 2016 originated in Seattle and flying to San Francisco International Airport1 and Ronald Reagan Washington National Airport2.

    The event marks a successful step toward new fuels that help airlines to reduce their greenhouse gas emissions (GHGs). Gevo’s alcohol to jet synthetic paraffinic kerosene (ATJ-SPK) process turns its bio-based isobutanol into jet fuel that meets the requirements of the recently revised ASTM D7566 (Standard Specification for Aviation Turbine Fuel Containing Synthesized Hydrocarbons) for up to a 30 percent fuel blend. The two Alaska Airlines flights on June 7, 2016 utilized a 20 percent fuel blend.

    When compared to other fuel options, Gevo believes that its renewable ATJ has the potential to offer the most optimized operating cost, capital cost, feedstock availability, scalability, and translation across geographies.

    These two commercial flights represent an important advance in biofuels for an industry that contributes about 2 percent of the total GHG emissions worldwide, according to the International Civil Aviation Organization, a United Nations agency. The agency also expects growth in air travel worldwide will result in double the number of passengers and flights by 2030. These additional flights will dramatically increase jet fuel consumption and GHG emissions.

  • Biofuel use for all Sea-Tac flights to reduce carbon emissions and support aviation biofuel development in Pacific Northwest
    SEATTLE, DEC. 16, 2015 – The Port of Seattle, Alaska Airlines [NYSE:ALK] and Boeing [NYSE:BA] are partnering to move toward a significant environmental goal: powering all flights by all airlines at Seattle-Tacoma International Airport with sustainable aviation biofuel. Sea-Tac is the first U.S. airport to lay out a long-term roadmap to incorporate aviation biofuel into its infrastructure in a cost-effective, efficient manner.

    At the Sea-Tac fuel farm today, executives for the port, Alaska Airlines, and Boeing signed a Memorandum of Understanding (MOU) to launch a $250,000 Biofuel Infrastructure Feasibility Study that will assess costs and infrastructure necessary to deliver a blend of aviation biofuel and conventional jet fuel to aircraft at Sea-Tac, a crucial step toward routine biofuel use in the future.

    “As leaders in aviation biofuels, this will send a signal to airlines and biofuel producers that Sea-Tac Airport will be ready to integrate commercial-scale use of aviation biofuels,” said Port of Seattle Commissioner John Creighton. “Biofuel infrastructure will make Sea-Tac Airport an attractive option for any airline committing to use biofuel, and will assist in attracting biofuel producers to the region as part of a longer-term market development strategy.”

    The partners’ longer-term plan is to incorporate significant quantities of biofuel into Sea-Tac’s fuel infrastructure, which is used by all 26 airlines and more than 380,000 flights annually at the airport. Sea-Tac is the 13th busiest airport in the U.S. and will serve over 42 million domestic and international passengers this year.

    Joe Sprague, senior vice president of communications and external relations for Alaska Airlines, Sea-Tac’s largest carrier and leader of the airport’s fueling consortium, said the airline wants to incorporate biofuel into flight operations at one or more of its hubs by 2020, with Sea-Tac as a first choice for the Seattle-based airline.

    “Biofuel offers the greatest way to further reduce our emissions,” said Sprague. “This study is a critical step in advancing our environmental goals and stimulating aviation biofuel production in the Pacific Northwest.”

    The Port of Seattle will manage the $250,000 study as the biofuel roadmapping process and, as Sea-Tac Airport’s governing authority, would handle the engineering and integration of biofuel infrastructure on Port property such as the airport’s fuel farm. An RFP for the infrastructure study will be issued in the spring of 2016, and the study is expected to be completed by late 2016. Currently, aviation biofuels are not produced in Washington state and must be imported by truck, rail or barge.

    Boeing, which partners globally to develop and commercialize sustainable aviation biofuel, is providing expertise about approaches to develop a regional biofuel supply chain to serve the airport, including fuel types, fuel producers, processing technologies and integration with airplanes.

    “Sustainable aviation biofuel will play a critical role in reducing aviation’s carbon emissions over the long term,” said Sheila Remes, Boeing Commercial Airplanes vice president of Strategy. “Boeing, Washington state’s largest employer, is proud to work with our customer Alaska Airlines and the Port of Seattle to power every plane at Sea-Tac with a biofuel blend and lead the way for other airports to do the same.”

    Approved “drop-in” aviation biofuel is blended directly with regular petroleum-based jet fuel and used in airplanes without any changes to the aircraft or engines. Using sustainably produced biofuel reduces lifecycle carbon dioxide emissions by 50 to 80 percent compared to conventional petroleum fuel, according to the U.S. Department of Energy. Since 2011, when biofuel was approved for commercial aviation, airlines have conducted more than 2,000 passenger flights with a blend of biofuel and conventional petroleum jet fuel.

    The Port’s Century Agenda Goal is to reduce aircraft-related carbon emissions at Sea-Tac Airport by 25% by 2037. The key strategy to reduce these emissions is through aviation biofuel. Historically, the Port has been a leader in supporting research and development of aviation biofuels, and as models of other international airports and airlines using biofuel emerge, Sea-Tac is also developing a market-support role.

    In the past five years, Alaska Airlines has become a leader in the pursuit of finding a sustainable supply of biofuels. In 2011, Alaska was the first airline to fly multiple flights using a 20 percent blend of sustainable aviation biofuel made from used cooking oil and waste animal fat.

    In the next year, Alaska will partner with Gevo, Inc. to fly the first ever commercial flight on alcohol-to-jet fuel. In addition, as a partner in the Washington State University-led Northwest Advanced Renewable Alliance (NARA), Alaska plans to fly a demonstration flight next year using a new aviation biofuel made from forest-industry waste. Fuel for both demonstration flights must first be independently certified.

    As part of Boeing’s commitment to protect the environment and support long-term sustainable growth for commercial aviation, the company partners globally with airlines, governments, research institutions, fuel companies and others to develop sustainable aviation biofuel. Boeing has active biofuel projects in the U.S., Australia, Brazil, Canada, China, Europe, Japan, the Middle East, South Africa and Southeast Asia

  • Mr. Lancelot most recently served as CEO of Outdoor Reservation Management Group, President of Enerjet LTD, and Senior Vice President and Chief Financial Officer for Spirit Airlines, Inc. Previously, his experience includes executive positions at AirTran Airways and Atlas Air Worldwide Holdings among others. Mr. Lancelot is specifically skilled in debt refinancing and restructuring, corporate governance, turnarounds, and process improvement. Some of his notable career achievements include raising hundreds of millions of dollars in public equity, financing billions of dollars’ worth of aircraft and successfully executing the turnaround of a low cost airline producing the highest EBITDAR margins of any carrier in the United States.

  • baxterjames120 baxterjames120 Jun 4, 2016 9:35 AM Flag

    Keep your eyes on Avid

  • 6-3-16: FBR’s Thomas Yip reiterated an Outperform rating on shares of PPHM (PT=$1.00), after the drug maker reported a preliminary financial update of the company and its wholly owned bio-manufacturing subsidiary, Avid Bioservices [ ]. Yip stated, “This financial update reaffirmed our belief that Avid will continue its organic growth, and we continue to think that Avid will remain a valuable source of non-dilutive cash flow for Peregrine as the company continues to explore opportunities to develop its lead asset, bavituximab, as a treatment combination with immuno-oncology agents. We also think Peregrine would not require addl. financing in the near term, as it reported a pro forma cash balance of $61mm as of April 30.”

    = = = = = =
    6-2-16/PR: Corp.Update – Avid Expansion & Drug Development - Avid revs for FY16(fye 4-30-16) will be $44mm; since $25.6mm for 1st 3 qtrs, Q4 revs will be ~$18.4mm. Avid B/L currently $56M; guidance for FY17(fye 4-30-17) is $50-55mm. Avid II (Myford) is currently ramping up for runs for “3 current clients”. Peregrine is “in the process of designing a 3rd mfg. Facility focused on clinical manufacturing”; has already secured a 25,000sf location, and “expects the new clinical suite to be complete & ready for clinical mfg. by 1H/2017.” ...All this leads to Peregrine expecting, "future sustainable profitability for the company in 24 months".

  • pretty good vote of confidence

  • this has been happening a lot lately. Out of thousands of publicly traded companies- why so much high profile visibility for little ole MGT? This is bizarre but I like it.

  • I sense that CEO confirmation for Mcafee is imminent.

15.75+0.72(+4.79%)Jun 28 4:00 PMEDT